Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2018

Conditions
Nephrotic Syndrome
Interventions
DRUG

ACTH

Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.

Trial Locations (16)

10467

Children's Hospital at Montefiore, The Bronx

19803

Nemours/AI duPont Hospital for Children, Wilmington

23298

Children's Hospital of Richmond at VCU, Richmond

27704

Duke Children's Health Center, Durham

27834

East Carolina University, Greenville

30322

Emory University, Atlanta

32827

Nemours Children's Hospital, Orlando

35205

Pediatric Nephrology of Alabama, PC., Birmingham

46202

Riley Hospital for Children, Indianapolis

49503

Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids

55905

Mayo Clinic, Rochester

64109

Children's Mercy, Kansas City

77030

Texas Children's Hospital, Houston

78411

Driscoll Children's Hospital, Corpus Christi

90095

University of California, Los Angeles, Los Angeles

02115

Boston Children's Hopsital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Emory University

OTHER